
Oramed Pharmaceuticals (ORMP) P/E Ratio
P/E Ratio as of Jun 13, 2025: -3.03
Average-3.15
Median-3.13
Minimum-3.41
Maximum-3.02
-3.03
Past Month+0.12 (3.81%)
The P/E ratio for Oramed Pharmaceuticals (ORMP) is -3.03 as of Jun 13, 2025. This represents a decrease of -128.42% compared to its 12-month average P/E ratio of 10.66. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Oramed Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Oramed Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Oramed Pharmaceuticals to industry peers.
Oramed Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Oramed Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Oramed Pharmaceuticals to industry peers.
Oramed Pharmaceuticals (ORMP) P/E Ratio Insights
See Oramed Pharmaceuticals’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Oramed Pharmaceuticals (ORMP)
Order type
Buy in
Order amount
Est. shares
0 shares
Oramed Pharmaceuticals (ORMP) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $2.38 | -3.41 |
May 1, 2025 | $2.27 | -4.76 |
Apr 1, 2025 | $2.13 | -4.47 |
Mar 3, 2025 | $2.00 | 18.35 |
Feb 3, 2025 | $2.16 | 19.82 |
Jan 2, 2025 | $2.41 | 22.11 |
Oramed Pharmaceuticals (ORMP) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -3.03 | -113.65% |
2024 | 22.20 | -494.32% |
2023 | -5.63 | -56.42% |
2022 | -12.92 | -30.43% |
2021 | -18.57 | +191.98% |
2020 | -6.36 | — |
FAQs About Oramed Pharmaceuticals (ORMP) P/E ratio
The latest P/E ratio of Oramed Pharmaceuticals (ORMP) is -3.03, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Oramed Pharmaceuticals’s last 12-month average P/E ratio is 10.66, compared to its current P/E ratio of -3.03. This reflects a decrease of -128.42%.
Oramed Pharmaceuticals’s current P/E ratio of -3.03 is lower than its last 12-month average P/E of 10.66. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Oramed Pharmaceuticals’s average P/E ratio over the last 3 years is 3.02. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Oramed Pharmaceuticals’s average P/E ratio over the last 5 years is -3.71. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.